87 related articles for article (PubMed ID: 11190365)
1. Urinary retention with reboxetine-fluoxetine combination in a young man.
Benazzi F
Can J Psychiatry; 2000 Dec; 45(10):936. PubMed ID: 11190365
[No Abstract] [Full Text] [Related]
2. Managing reboxetine-associated urinary hesitancy in a patient with major depressive disorder: a case study.
Kasper S
Psychopharmacology (Berl); 2002 Feb; 159(4):445-6. PubMed ID: 11823898
[No Abstract] [Full Text] [Related]
3. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
Fava M; McGrath PJ; Sheu WP;
J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
[TBL] [Abstract][Full Text] [Related]
4. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder.
Clayton AH; Zajecka J; Ferguson JM; Filipiak-Reisner JK; Brown MT; Schwartz GE
Int Clin Psychopharmacol; 2003 May; 18(3):151-6. PubMed ID: 12702894
[TBL] [Abstract][Full Text] [Related]
5. Sleepwalking associated with reboxetine in a young female patient with major depression--a case report.
Künzel HE; Schuld A; Pollmächer T
Pharmacopsychiatry; 2004 Nov; 37(6):307-8. PubMed ID: 15551201
[No Abstract] [Full Text] [Related]
6. Noradrenergic adverse effects due to combined treatment with reboxetine and triiodothyronine.
Cooper-Kazaz R; Cohen A; Lerer B
J Clin Psychopharmacol; 2010 Apr; 30(2):211-2. PubMed ID: 20520303
[No Abstract] [Full Text] [Related]
7. Doxazosin for reboxetine-induced urinary hesitancy.
Szabadi E
Br J Psychiatry; 1998 Nov; 173():441-2. PubMed ID: 9926068
[No Abstract] [Full Text] [Related]
8. Fluoxetine associated with thrombocytopenia and treatment with reboxetine: 3 cases.
Yucel A; Yucel N; Ozcan H; Gulec M; Aydin A
J Clin Psychopharmacol; 2015 Jun; 35(3):354-5. PubMed ID: 25822478
[No Abstract] [Full Text] [Related]
9. Reboxetine addition in patients with mirtazapine-resistant depression: a case series.
López-Muñoz F; Rubio G; Alamo C; García-García P; Pardo A
Clin Neuropharmacol; 2006; 29(4):192-6. PubMed ID: 16855420
[TBL] [Abstract][Full Text] [Related]
10. Fluoxetine in the treatment of cyclic mood disorders.
Brodsky L
Psychiatr J Univ Ott; 1990 Nov; 15(4):237. PubMed ID: 2284378
[No Abstract] [Full Text] [Related]
11. Fluoxetine-mirtazapine interaction may induce restless legs syndrome: report of 3 cases from a clinical trial.
Prospero-Garcia KA; Torres-Ruiz A; Ramirez-Bermudez J; Velazquez-Moctezuma J; Arana-Lechuga Y; Teran-Perez G
J Clin Psychiatry; 2006 Nov; 67(11):1820. PubMed ID: 17196069
[No Abstract] [Full Text] [Related]
12. Urinary retention with fluoxetine-haloperidol combination in a young patient.
Benazzi F
Can J Psychiatry; 1996 Nov; 41(9):606-7. PubMed ID: 8946091
[No Abstract] [Full Text] [Related]
13. Successful treatment of reboxetine-induced urinary hesitancy with tamsulosin.
Kasper S; Wolf R
Eur Neuropsychopharmacol; 2002 Apr; 12(2):119-22. PubMed ID: 11872327
[TBL] [Abstract][Full Text] [Related]
14. Reboxetine and treatment-refractory elderly patients with depression.
Chue P
Can J Psychiatry; 2000 Sep; 45(7):669. PubMed ID: 11056834
[No Abstract] [Full Text] [Related]
15. Reboxetine induced erectile dysfunction and spontaneous ejaculation during defecation and micturition.
Sivrioglu EY; Topaloglu VC; Sarandol A; Akkaya C; Eker SS; Kirli S
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):548-50. PubMed ID: 17123681
[TBL] [Abstract][Full Text] [Related]
16. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
Langworth S; Bodlund O; Agren H
J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139
[TBL] [Abstract][Full Text] [Related]
18. Asymptomatic reboxetine overdose.
Bandinelli PL; Polselli GM
Int J Neuropsychopharmacol; 2006 Apr; 9(2):257. PubMed ID: 15967062
[No Abstract] [Full Text] [Related]
19. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder.
Jazayeri S; Tehrani-Doost M; Keshavarz SA; Hosseini M; Djazayery A; Amini H; Jalali M; Peet M
Aust N Z J Psychiatry; 2008 Mar; 42(3):192-8. PubMed ID: 18247193
[TBL] [Abstract][Full Text] [Related]
20. Possible adverse drug interactions between fluoxetine and other psychotropics.
Lock JD; Gwirtsman HE; Targ EF
J Clin Psychopharmacol; 1990 Oct; 10(5):383-4. PubMed ID: 2258459
[No Abstract] [Full Text] [Related]
[Next] [New Search]
